Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | SELE | P16581 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973858 | 0.91 | HCAR2 (0.57) | HCAR2RAB9ASELPSELEGAA | |
| SCHEMBL9973839 | 0.90 | HCAR2 (0.65) | HCAR2SELPSELECYP2C9KDM6B | |
| SCHEMBL14515856 | 0.86 | HCAR2 (0.64) | HCAR2RAB9ACYP2C9 | |
| SCHEMBL6102348 | 0.86 | HCAR2 (0.75) | HCAR2 | |
| SCHEMBL14227346 | 0.84 | GAA (0.61) | RAB9AGAAPOLB | |
| SCHEMBL9973837 | 0.83 | HCAR2 (0.63) | HCAR2SELPSELECYP2C9KDM6B | |
| SCHEMBL18520605 | 0.81 | HCAR2 (0.77) | HCAR2RAB9A | |
| SCHEMBL14290037 | 0.81 | HCAR2 (0.51) | HCAR2RAB9ASELPSELECYP2C9 | |
| SCHEMBL14290082 | 0.79 | HCAR2 (0.54) | HCAR2RAB9ASELPSELECYP2C9 | |
| SCHEMBL14290043 | 0.79 | ALOX5 (0.58) | HCAR2RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| EP-1959915-B1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE AG (DE) | 2015-05-13 | — | — | EP | disclosed |
| EP-1886662-A1 | Anti-microbial compounds for treating bad breath | Symrise GmbH & Co. KG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007062957-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | OAT, PIGS, HLA-A | HCAR2 2384/4885RAB9A 3488/4885SELP 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.